Daniel Radiloff, PhD, is director of Business Development, Pacific BioLabs.

Daniel Radiloff

Scientist holding liquid biological sample. Medical technology research institute concept, molecule inside liquid bubble, 3d illustration. | Image Credit - © fgnopporn - © fgnopporn - stock.adobe.com

To reduce costs and streamline their internal processes, bio/pharmaceutical and biotech companies are increasingly outsourcing many of their internal operations related to the development of their therapeutic compounds, including preclinical testing. That said, contract research organizations (CROs) are playing a more important role in providing critical testing services required for internal validation purposes and submission to regulatory agencies. Navigating the preclinical testing process can be a somewhat confusing, if not difficult, task including identifying the proper partner for conducting the necessary studies to help advance a promising lead compound from the discovery phase to the initiation of investigational new drug (IND) process. This article will serve as a useful guide, including why/when to outsource preclinical testing, the advantages and disadvantages of outsourcing this testing, and how to effectively choose a partner to conduct this testing.

Navigating the Preclinical CRO Outsourcing Process

Pharmaceutical Technology/Pharmaceutical Technology Europe Outsourcing Innovation eBook February 2024

Pharmaceutical Technology/Pharmaceutical Technology Europe Outsourcing Innovation

 eBook
Issue 2
February 2024
Pages: 10-14

When referring to this article, please cite it as Radiloff, D. Navigating the Preclinical CRO Outsourcing Process. 

Articles

The need for preclinical testing expertise is growing as molecular complexity increases.